DDInter1763 DDInter833
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Temsirolimus {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Temsirolimus {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Glycerol phenylbutyrate
Temsirolimus {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Glycerol phenylbutyrate
Temsirolimus {u} (Compound) resembles {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Temsirolimus (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Temsirolimus (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Alverine (Compound) and Alverine (Compound) resembles Glycerol phenylbutyrate (Compound)
Temsirolimus (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Alverine (Compound) and Alverine (Compound) resembles Glycerol phenylbutyrate (Compound)
Temsirolimus (Compound) resembles Tacrolimus (Compound) and Tacrolimus (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)